Genocea Biosciences was founded in 2006 to commercialize key
breakthroughs in vaccine discovery and development. When they work,
vaccines are one of the most effective ways of preventing and
treating disease. Unfortunately, many research and clinical vaccine
programs are hit-and-miss because there is currently no way to
screen all possible antigens or predict which ones will work.
To remove the guesswork, we need the ability to mimic the human
immune system in vitro so one can identify which antigenic
epitopes will elicit a competent immune response.
Genocea can rapidly identify antigens that result in the in
vivo stimulation of protective CD8+ and CD4+ T-cells,
targets that can be immediately incorporated into existing antigen
delivery systems to produce multivalent vaccine formulations that
have the highest probability of generating protective cell-mediated
immunity.
|
|
